세계의 대사체학 시장

Global Metabolomics Market to Reach US$7.1 Billion by 2030

The global market for Metabolomics estimated at US$3.3 Billion in the year 2023, is expected to reach US$7.1 Billion by 2030, growing at a CAGR of 11.6% over the analysis period 2023-2030. Cancer Indication, one of the segments analyzed in the report, is expected to record a 13.0% CAGR and reach US$3.6 Billion by the end of the analysis period. Growth in the Cardiovascular Disorder Indication segment is estimated at 10.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 14.0% CAGR

The Metabolomics market in the U.S. is estimated at US$1.3 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$687.2 Million by the year 2030 trailing a CAGR of 14.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.5% and 11.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.6% CAGR.

Global Metabolomics Market – Key Trends & Drivers Summarized

How Is Metabolomics Unlocking New Frontiers in Biological Research?

Metabolomics, the comprehensive study of metabolites in biological systems, is revolutionizing the way researchers understand cellular processes, disease mechanisms, and therapeutic interventions. This cutting-edge field provides insights into the biochemical pathways that govern health and disease by analyzing small molecules within cells, tissues, or biofluids. The rise of metabolomics has enabled scientists to uncover biomarkers for early disease detection, monitor drug efficacy, and personalize treatments for various conditions, including cancer, cardiovascular diseases, and metabolic disorders. Advanced analytical technologies, such as mass spectrometry (MS) and nuclear magnetic resonance (NMR), are central to metabolomics research, allowing for the accurate detection and quantification of complex metabolite profiles. As the demand for precision medicine continues to grow, metabolomics is becoming an indispensable tool in modern biomedical research.

Why Are Pharmaceutical and Healthcare Sectors Investing in Metabolomics?

The pharmaceutical and healthcare sectors are leveraging metabolomics to accelerate drug discovery and enhance patient outcomes. By identifying disease-specific metabolic signatures, researchers can develop targeted therapies and improve the success rates of clinical trials. In drug development, metabolomics facilitates the screening of potential drug candidates, optimizing efficacy while minimizing adverse effects. The technology is also gaining traction in nutritional science, where it is used to evaluate dietary interventions and their impact on metabolic health. Clinical laboratories are increasingly adopting metabolomics for diagnostic purposes, offering more accurate and comprehensive assessments of diseases. Furthermore, the growing emphasis on personalized medicine is driving investments in metabolomics, enabling healthcare providers to tailor treatments to individual patient profiles. This surge in demand is fostering innovation and collaboration between academic institutions, pharmaceutical companies, and diagnostic firms.

How Are Technological Advances Shaping the Metabolomics Landscape?

Technological advancements are at the heart of metabolomics, enhancing the resolution, accuracy, and speed of metabolite analysis. Innovations in high-throughput mass spectrometry and chromatography techniques are enabling the simultaneous detection of thousands of metabolites, providing a holistic view of biological systems. Bioinformatics and machine learning are playing a pivotal role in metabolomics, allowing researchers to analyze large datasets, identify patterns, and derive meaningful insights from complex metabolomic profiles. The integration of multi-omics approaches, combining metabolomics with genomics, proteomics, and transcriptomics, is expanding the scope of research and uncovering new layers of biological complexity. Cloud-based platforms and open-access databases are facilitating global collaboration, making metabolomic data more accessible and enabling cross-disciplinary research. These technological advancements are driving the adoption of metabolomics in diverse fields, from drug development to environmental monitoring, cementing its position as a cornerstone of modern science.

What Factors Are Driving Growth in the Metabolomics Market?

The growth in the metabolomics market is driven by several factors, including the increasing prevalence of chronic diseases, which necessitate advanced diagnostic tools and personalized treatment approaches. The rising demand for precision medicine is a key driver, as metabolomics offers unparalleled insights into individual health profiles and therapeutic responses. Technological innovations, such as advancements in mass spectrometry, NMR, and bioinformatics, are making metabolomic analysis more efficient, accurate, and accessible, attracting investments from pharmaceutical and biotechnology companies. The expansion of multi-omics research is also propelling the adoption of metabolomics, as it enables a comprehensive understanding of biological systems. Furthermore, the growing awareness of the role of nutrition and metabolism in health management is driving the application of metabolomics in personalized nutrition and wellness programs. Collaborative efforts between academia, industry, and regulatory bodies are fostering innovation and standardization in the field, further accelerating market growth. These factors highlight the transformative potential of metabolomics in shaping the future of healthcare and biomedical research.

SCOPE OF STUDY:

The report analyzes the Metabolomics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication, Other Indications); Application (Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application, Other Applications); End-Use (Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use, Other End-Uses)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 63 Featured) -

• AB Sciex LLC
• Agilent Technologies, Inc.
• Biocrates Life Sciences Ag
• Bruker Corporation
• Chenomx, Inc.
• GL Sciences Inc.
• Human Metabolome Technologies, Inc.
• LECO Corporation
• Metabolon, Inc.
• PerkinElmer, Inc.
• Shimadzu Scientific Instruments
• Thermo Fisher Scientific, Inc.
• Waters Corporation

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Metabolomics: Transforming Healthcare with Insight into Metabolic Pathways and Biomarkers
  • Global Economic Update
  • EXHIBIT 1: World Economic Growth Projections (Real Gross Domestic Product (GDP), Annual % Change) for the Years 2022 Through 2025
  • EXHIBIT 2: Global Headline Inflation Rates (In %) for the Years 2019 through 2025
  • EXHIBIT 3: Global Average Annual Brent Crude Oil Price (In US$ Per Barrel) for Years 2019 through 2025
  • Competition
  • EXHIBIT 4: Metabolomics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Introduction to Metabolomics
  • Analytical Techniques in Metabolomics
  • The Metabolomics Workflow: Key Stages
  • Applications of Metabolomics
  • Recent Market Activity
  • Influencer/Product/Technology Insights
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Development of Novel Biomarkers for Disease Detection Drives Widespread Adoption of Metabolomics in Clinical Diagnostics
  • Metabolomics in Drug Research and Development: A Pathway to Precision Medicine
  • Growing Focus on Personalized Healthcare and Patient-Centric Solutions Expands Addressable Market for Targeted Metabolomics Applications
  • EXHIBIT 5: Global Personalized Medicine Market: Revenues in US$ Million for the Years 2019, 2021, 2023 and 2025
  • Growing Multidisciplinary Role of Metabolomics in Toxicology Testing
  • Rising Demand for Nutrigenomics Throws the Spotlight on Nutritional Metabolomics Applications for Customized Diet Planning
  • Growing Investment in Cancer Research Propels Growth in Oncology-Focused Metabolomics Studies and Applications
  • EXHIBIT 6: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2022 and 2050
  • EXHIBIT 7: Global Cancer Incidence by Region: 2022
  • Integration of AI, Machine Learning, and Big Data Analytics Expands the Potential of Metabolomics Data for Predictive Modeling and Insights
  • Advancements in Mass Spectrometry and Analytical Tools Strengthen the Business Case for Large-Scale Metabolomics Research
  • Global Shift Toward Precision Medicine Accelerates Adoption Of Metabolomics
  • Role of Metabolomics in Inborn Errors of Metabolism (IEMs): Current Advancements and Future Directions
  • Harnessing Metabolomics for Crop Improvement and Sustainable Agriculture
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Metabolomics Market Analysis of Annual Sales in US$ Thousand for Years 2018 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Metabolomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Metabolomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 4: World 12-Year Perspective for Metabolomics by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2018, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Cancer Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 7: World 12-Year Perspective for Cancer Indication by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Cardiovascular Disorder Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Cardiovascular Disorder Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 10: World 12-Year Perspective for Cardiovascular Disorder Indication by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Neurological Disorder Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Neurological Disorder Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 13: World 12-Year Perspective for Neurological Disorder Indication by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Inborn Errors of Metabolism Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Inborn Errors of Metabolism Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 16: World 12-Year Perspective for Inborn Errors of Metabolism Indication by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 19: World 12-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Biomarker Discovery Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Biomarker Discovery Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 22: World 12-Year Perspective for Biomarker Discovery Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Drug Discovery Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Drug Discovery Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 25: World 12-Year Perspective for Drug Discovery Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Toxicology Testing Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Toxicology Testing Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 28: World 12-Year Perspective for Toxicology Testing Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Nutrigenomics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Nutrigenomics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 31: World 12-Year Perspective for Nutrigenomics Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Personalized Medicine Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Personalized Medicine Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 34: World 12-Year Perspective for Personalized Medicine Application by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 37: World 12-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 40: World 12-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 43: World 12-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Contract Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Contract Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 46: World 12-Year Perspective for Contract Research Organizations End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 49: World 12-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Metabolomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Market Analytics
  • TABLE 50: USA Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 52: USA 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 55: USA 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 58: USA 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030
• CANADA
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 61: Canada 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 64: Canada 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 67: Canada 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030
• JAPAN
  • Metabolomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Market Analytics
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 70: Japan 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 73: Japan 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 76: Japan 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030
• CHINA
  • TABLE 77: China Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 79: China 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 82: China 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 85: China 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030
• EUROPE
  • Metabolomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Market Analytics
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Metabolomics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Metabolomics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 88: Europe 12-Year Perspective for Metabolomics by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2018, 2024 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 91: Europe 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 94: Europe 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 97: Europe 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030
• FRANCE
  • TABLE 98: France Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 100: France 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030
  • TABLE 101: France Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 103: France 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030
  • TABLE 104: France Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 106: France 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030
• GERMANY
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 109: Germany 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030
  • TABLE 110: Germany Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Germany Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 112: Germany 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030
  • TABLE 113: Germany Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 115: Germany 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030
• ITALY
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 118: Italy 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030
  • TABLE 119: Italy Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 120: Italy Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 121: Italy 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030
  • TABLE 122: Italy Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 123: Italy Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 124: Italy 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030
• UNITED KINGDOM
  • TABLE 125: UK Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 127: UK 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030
  • TABLE 128: UK Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 129: UK Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 130: UK 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030
  • TABLE 131: UK Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 132: UK Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 133: UK 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030
• REST OF EUROPE
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 136: Rest of Europe 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 139: Rest of Europe 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 142: Rest of Europe 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030
• ASIA-PACIFIC
  • Metabolomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Market Analytics
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 145: Asia-Pacific 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 148: Asia-Pacific 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 151: Asia-Pacific 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030
• REST OF WORLD
  • TABLE 152: Rest of World Recent Past, Current & Future Analysis for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Rest of World Historic Review for Metabolomics by Indication - Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 154: Rest of World 12-Year Perspective for Metabolomics by Indication - Percentage Breakdown of Value Revenues for Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication and Other Indications for the Years 2018, 2024 & 2030
  • TABLE 155: Rest of World Recent Past, Current & Future Analysis for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Rest of World Historic Review for Metabolomics by Application - Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 157: Rest of World 12-Year Perspective for Metabolomics by Application - Percentage Breakdown of Value Revenues for Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application and Other Applications for the Years 2018, 2024 & 2030
  • TABLE 158: Rest of World Recent Past, Current & Future Analysis for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Rest of World Historic Review for Metabolomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2018 through 2022 and % CAGR
  • TABLE 160: Rest of World 12-Year Perspective for Metabolomics by End-Use - Percentage Breakdown of Value Revenues for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2018, 2024 & 2030

IV. COMPETITION